SMS Pharma Gets EIR for Hyderabad API Facility
ECONOMY & POLICY

SMS Pharma Gets EIR for Hyderabad API Facility

SMS Pharmaceuticals Limited announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility at Bachupally, Hyderabad. The inspection was conducted between 17th and 21st March 2025.

The inspection concluded with one procedural observation on Form 483, which has already been addressed by the company. The issuance of the EIR marks the formal closure of the audit.

The Hyderabad unit has a manufacturing capacity of 120 kilolitres and specialises in niche, small-volume, high-value molecules. It holds multiple global regulatory approvals including those from USFDA, European Union Good Manufacturing Practice (EU GMP), Korea Food and Drug Administration (KFDA), Brazilian Health Regulatory Agency (ANVISA), Pharmaceuticals and Medical Devices Agency (PMDA), and Central Drugs Standard Control Organisation (CDSCO).

Established in 1990, SMS Pharma serves global clients across over seventy countries, with facilities in Hyderabad and Vizag. The company is supported by in-house research and development capabilities and operates in a wide range of therapeutic categories.

Source:
SMS Pharmaceuticals Limited 

Your next big infra connection is waiting at RAHSTA 2025 – Asia’s Biggest Roads & Highways Expo, Jio World Convention Centre, Mumbai. Don’t miss out!

SMS Pharmaceuticals Limited announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility at Bachupally, Hyderabad. The inspection was conducted between 17th and 21st March 2025. The inspection concluded with one procedural observation on Form 483, which has already been addressed by the company. The issuance of the EIR marks the formal closure of the audit. The Hyderabad unit has a manufacturing capacity of 120 kilolitres and specialises in niche, small-volume, high-value molecules. It holds multiple global regulatory approvals including those from USFDA, European Union Good Manufacturing Practice (EU GMP), Korea Food and Drug Administration (KFDA), Brazilian Health Regulatory Agency (ANVISA), Pharmaceuticals and Medical Devices Agency (PMDA), and Central Drugs Standard Control Organisation (CDSCO). Established in 1990, SMS Pharma serves global clients across over seventy countries, with facilities in Hyderabad and Vizag. The company is supported by in-house research and development capabilities and operates in a wide range of therapeutic categories. Source: SMS Pharmaceuticals Limited 

Next Story
Infrastructure Transport

Indian Railways Marks New Milestone with 4.5 km Long ‘Rudrastra’ Trial

Indian Railways has successfully conducted the trial run of Asia’s longest freight train, named ‘Rudrastra’, achieving a new milestone in cargo transportation, as per news reports. The 4.5 km-long train began its trial from Ganjkhwaja railway station in Chandauli, Uttar Pradesh, and travelled to Garhwa in Jharkhand. Covering a distance of 209 km in 5 hours and 10 minutes, it maintained an average speed of 40.5 km per hour. The train was formed by combining three long-haul racks, with ..

Next Story
Infrastructure Energy

UltraTech Launches India’s First On-Site Hybrid RTC Renewable Energy Project

UltraTech Cement has operationalised a 7.5 MW round-the-clock (RTC) hybrid renewable energy project at its Sewagram Cement Works in Gujarat. The first-of-its-kind solution combines bifacial solar modules with trackers, wind energy and battery storage, co-located on-site, to ensure uninterrupted power for cement manufacturing without grid reliance. The project was executed in collaboration with clean energy solutions provider Gentari. Installed as a behind-the-meter system, it is the country..

Next Story
Infrastructure Transport

Patna Metro Trials Successful, Red Line Priority Corridor to Launch This Month

Patna is set to roll out its first metro rail service later this month, with successful trial runs conducted on the Red Line priority corridor, the Patna Metro Rail Corporation announced.On 7 September, a metro train completed a test run between the Patna depot and Bhootnath station. Officials said the trials involved rigorous checks of rolling stock fitness, overhead electrification (OHE), and track alignment and stability to ensure operational safety and performance.The corridor from the New Pataliputra Bus Terminal to Bhoothnath has been designated as the priority stretch and will be the fi..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?